Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014

Tuberculosis (TB) causes a large degree of suffering and an estimated 1.3 million deaths per year globally, occurring mainly in less affluent countries, but also in upper-middle and high-income countries in the European Union/European Economic Area (EU/EEA) [1,2]. In Europe, there has been a steady decline in TB notification rates of ca 5% per year. Nevertheless, TB remains a considerable problem because of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB [3].